<SEC-DOCUMENT>0001372514-24-000068.txt : 20240701
<SEC-HEADER>0001372514-24-000068.hdr.sgml : 20240701
<ACCEPTANCE-DATETIME>20240701070032
ACCESSION NUMBER:		0001372514-24-000068
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240628
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240701
DATE AS OF CHANGE:		20240701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		241088149

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20240628.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3c62026a-7aae-40c2-97f2-d20405ae5303,g:4f7b8042-8109-49f0-8333-76a8b38680dd,d:bca09915808d4f3da40b4d9bde8c9d29-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20240628</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20240628.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibca09915808d4f3da40b4d9bde8c9d29_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">June 28, 2024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-20">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibca09915808d4f3da40b4d9bde8c9d29_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Appointment of Director</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 1, 2024 (the &#8220;Effective Date&#8221;), the Board of Directors (the &#8220;Board&#8221;) of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">appointed Lisa Walters-Hoffert as a member of the Board to fill the vacancy resulting from the resignation of Kenneth Gayron as described below.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms. Walters-Hoffert will serve as a Class II director and will serve until the Company&#8217;s 2026 Annual Meeting of Stockholders and until her respective successor is duly elected and qualified or her earlier resignation or removal. Ms. Walters-Hoffert will also serve as chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Board has determined that Ms. Walters-Hoffert is independent under the rules of The Nasdaq Capital Market. As a non-employee director of the Company, Ms. Walters-Hoffert will receive compensation in the same manner of the Company&#8217;s other non-employee directors, as further described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms. Walters-Hoffert, age 65, was a co-founder of Dar&#233; Bioscience, Inc. and following the company&#8217;s merger with Cerulean Pharma, Inc. in July of 2017, became Chief Financial Officer of the surviving public company (Nasdaq: DARE) through January 2024. Ms. Walters-Hoffert previously served as an investment banker focused on small-cap public companies in the technology and life science sectors. From 2003 to 2015, Ms. Walters-Hoffert worked at Roth Capital Partners as Managing Director in the Investment Banking Division. Ms. Walters-Hoffert has held various positions in the corporate finance and investment banking divisions of Citicorp Securities in San Jos&#233;, Costa Rica and Oppenheimer &amp; Co, Inc. in New York City, New York. Since 2019, Ms. Walters-Hoffert has served on the board of Flux Power Holdings, Inc. (Nasdaq: FLUX), a developer of advanced lithium-ion energy storage solutions, where she serves as chair of the Audit Committee and member of the Compensation Committee and Nominating and Corporate Governance Committee. Ms. Walters-Hoffert has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian&#8217;s Advisory Board, and as Past Chair of the Board of Directors of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert currently serves as a member of the Board of Directors of The Elementary Institute of Science in San Diego. Ms. Walters-Hoffert graduated from Duke University with a B.S. in Management Sciences. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no arrangements or understandings between Ms. Walters-Hoffert and any other person pursuant to which Ms. Walters-Hoffert was appointed as a director of the Company, and there are no family relationships between Ms. Walters-Hoffert and any director or executive officer of the Company. Since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which Ms. Walters-Hoffert was or is to be a participant and in which any related person had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Appointment of Chief Financial Officer</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On the Effective Date, the Company appointed Melissa Tosca, CPA as the Chief Financial Officer of the Company.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms. Tosca, age 44, has served as the Company&#8217;s Executive Vice President of Finance and its principal financial and accounting officer since September 2022. </span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms. Tosca previously served as Executive Director of Finance and Corporate Treasurer for Neomorph from 2021 to 2022, where she managed the finance and accounting functions. She also served as Director of Finance and Accounting at Omniome from 2017 to 2021, building the accounting and finance infrastructure and managing financial operations. Prior to Omniome, she spent nine years at Caris Life Sciences from 2008 to 2017, serving in various leadership roles including Director of Finance and Accounting, Director of Financial Planning and Analysis and Senior Director of Sales Operations. She began her professional career in public accounting at Clifton Gunderson and later moved to Ernst &amp; Young as an Audit Manager. Ms. Tosca is a Certified Public Accountant and holds a BS in Accounting from the University of Arizona.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with Ms. Tosca&#8217;s appointment as Executive Vice President of Finance, the Company entered into an Offer Letter with Ms. Tosca on August 18, 2022 and effective as of September 13, 2022. Pursuant to the offer letter, Ms. Tosca received an annual base salary of&#8201;$300,000 and she was entitled to receive a performance bonus with a target of up to 25% of her annual base salary for the applicable fiscal year. Effective </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective Date</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Ms. Tosca's annual base salary was increased to $337,000 and her target bonus percentage was increased to 40%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no family relationships between Ms. </span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tosca </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and any director or executive officer of the Company. Since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which Ms. </span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tosca </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was or is to be a participant and in which any related person had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Resignation of Director</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 29, 2024, Kenneth Gayron notified the Board that he would resign as a member of the Board and from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Gayron did not resign as a result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Compensation Changes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective as of the Effective Date, the Compensation Committee approved increases to the salaries and target bonus opportunity percentages for the Company&#8217;s executive officers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Brian M. Strem, Ph.D., the Company&#8217;s President and Chief Executive Officer, will receive a base salary of $569,000 and a target bonus opportunity of 55%.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eric Daniels, MD, MBA, the Company&#8217;s Chief Development Officer, will receive a base salary of $443,000 and a target bonus opportunity of 40%.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Melissa Tosca, the Company&#8217;s Chief Financial Officer, will receive a base salary of $337,000 and a target bonus opportunity of 40%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Non-Employee Director Compensation Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also as of the Effective Date, the Board approved a revised non-employee director compensation policy to increase the additional cash retainer amount payable to the chair of the Board and to the chair of the Nominating and Corporate Governance Committee based upon the recommendation of the Compensation Committee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The policy, as revised, is set forth below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Compensation of Independent Non-Employee Directors Upon Initial Election to the Board</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each new independent non-employee member that is elected to the Board will receive a grant of 1,778 non-statutory stock options under the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;Plan&#8221;). Such option will be granted following his or her initial election to the Board and will be a non-statutory stock option to purchase shares of common stock with an exercise price equal to the fair market value of the Company&#8217;s common stock on the grant date. The initial option grant will vest with respect to all of the underlying shares on the first anniversary of the applicable grant date. For purposes of the director grant program, an independent non-employee director is a director who is not employed by the Company and who does not receive compensation from the Company (excluding the non-employee director compensation described herein) or have a business relationship with the Company that would require disclosure under certain SEC rules, and who has been determined to be independent as defined in Nasdaq Rule 5605(a)(2) by the Board.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Annual Equity Compensation of Independent Non-Employee Directors</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On a date determined by the Board in its discretion, each independent non-employee director will be eligible to receive a non-statutory stock option to purchase 1,778 shares of the Company&#8217;s common stock with an exercise price equal to the fair market value of the Company&#8217;s common stock on the grant date. An independent non-employee director who receives an initial award will not receive the additional annual award in the same calendar year. Annual grants vest in full on the one-year anniversary of the grant date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Annual Cash Compensation of Non-Employee Directors</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each independent non-employee director is entitled to receive the following cash compensation for board services, as applicable: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$40,000 per year for service as a board of directors member other than non-executive chairman or lead independent director;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$70,000 per year for service as non-executive chairman or lead independent director of the board of directors;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$15,000 per year for service as chairman of the audit committee;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$15,000 per year for service as chairman of the compensation committee;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$8,000 per year for service as chairman of the nominating and corporate governance committee;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$10,000 per year for service as non-chairman member of the audit committee;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$7,500 per year for service as non-chairman member of the compensation committee; and</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"/><td style="width:2.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">$5,000 per year for service as non-chairman member of the nominating and corporate governance committee.</span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Adjustment for Meeting Attendance</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of the cash amounts payable to independent non-employee directors listed above shall be reduced with respect to any given calendar year proportionally to the extent that a director does not attend, either telephonically or in person, more than 25% of the meetings of the Board or committees thereof on which such director serves, as applicable.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div id="ibca09915808d4f3da40b4d9bde8c9d29_10"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 7.01.    Regulation FD Disclosure.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 1, 2024, the Company issued a press release announcing the appointment of Ms. Walters-Hoffert as a member of the Board, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is an inactive textual references only.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ibca09915808d4f3da40b4d9bde8c9d29_13"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01.&#160;&#160;&#160;&#160;Other Events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 28, 2024, the Company received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). </span></div><div style="text-align:justify"><span><br/></span></div><div id="ibca09915808d4f3da40b4d9bde8c9d29_16"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991.htm">Press Release of Kiora Pharma</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991.htm">ceuticals, Inc. date</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991.htm"> July 1, 2024</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibca09915808d4f3da40b4d9bde8c9d29_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.841%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: July 1, 2024</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic0d5b4a560b7485b84fcb7e830a2942f_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Ken Gayron to Step Down as a Member of the Company&#8217;s Board</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">July 1, 2024 -- Encinitas, California</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -- Kiora Pharmaceuticals, Inc. (NASDAQ&#58; KPRX) (&#8220;Kiora&#8221; or the &#8220;Company&#8221;) today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors.  Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company&#8217;s board. Ms. Walters-Hoffert will serve as chair of the audit committee and as a member of the compensation committee. Concurrent with her appointment, Ken Gayron, current chair of the audit committee, will step down as a director of the Company&#8217;s board due to other work commitments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We welcome Lisa to our board and look forward to her guidance through our next phase of growth,&#8221; said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. &#8220;Her insight and experience will play a valuable role on behalf of our shareholders as we advance our current pipeline of investigational treatments for retinal diseases. The board and I also express our deep gratitude to Ken for his years of contributions as a director, having played an invaluable role in our strategic pivot towards becoming an innovative retinal therapeutics company.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;The past year has been a significant time for Kiora, with management delivering strong results in multiple areas,&#34; commented Ms. Walters-Hoffert. &#34;Since November 2023, Kiora reported promising data from KIO-301 targeting rare inherited retinal diseases&#59; established a strategic co-development and commercialization partnership&#59; capitalized the company with an expected runway for at least the next two years&#59; and now have the financial resources to invest in KIO-104, another novel therapy aimed at addressing multiple types of inflammatory retinal diseases that often leads to vision loss in patients. I am honored to have the opportunity to work with the exceptional management team and Board of Kiora to continue building value for patients and shareholders.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Lisa Walters-Hoffert</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Walters-Hoffert was a co-founder of Dar&#233; Bioscience, Inc. and following the company&#8217;s merger with Cerulean Pharma, Inc. in July of 2017, became Chief Financial Officer of the resulting public company (NASDAQ&#58; DARE). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more than twenty-five years, Ms. Walters-Hoffert served as an investment banker focused on small-cap public companies in the life science and technology sectors. From 2003 to 2015, Ms. Walters-Hoffert worked at Roth Capital Partners as Managing Director in the Investment Banking Division. Ms. Walters-Hoffert has also held various positions in the corporate finance and investment banking divisions of Citicorp Securities and Oppenheimer &#38; Co, Inc. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Walters-Hoffert currently serves as a director for Flux Power Holdings, Inc. and is a member of the Board of Directors of The Elementary Institute of Science. Additionally, she has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian&#8217;s Advisory Board, and as the Past Chair of the Board of Directors of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert graduated </font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">magna cum laude</font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Duke University with a B.S. in Management Sciences. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Kiora Pharmaceuticals</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-104 is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to news releases and SEC filings, we expect to post information on our website (</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.kiorapharma.com</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, and Kiora's plans to further fund development of KIO-104. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to satisfy the closing conditions related to the offering ,the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on May 10, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kiora Investor Relations </font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">investors&#64;kiorapharma.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media </font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">kiora&#64;crowepr.com</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crowe PR</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>kprx-20240628.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3c62026a-7aae-40c2-97f2-d20405ae5303,g:4f7b8042-8109-49f0-8333-76a8b38680dd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20240628" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20240628">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20240628_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20240628_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>kprx-20240628_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3c62026a-7aae-40c2-97f2-d20405ae5303,g:4f7b8042-8109-49f0-8333-76a8b38680dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_5107d1a6-9f20-4529-bf84-fa2b1db24012_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2133ea5d-1e8e-4d04-9d0d-48f2712d7799_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ecba448b-1931-480d-a79c-2aa8190aa704_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5bb67f7d-35f3-4eb8-b3ca-26c0947939ff_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_27d8c38b-6930-414b-9f42-b4b1c7c15a4f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4cf458f9-b71d-435b-af83-441e404480a3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7f763f45-7142-4c51-8751-b9e6a6cbb11f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_354bec55-1aef-48cc-bf33-386e517f4d80_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d49869bc-0835-44c1-8e7d-80e8d0b26266_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a9de3bde-298a-4d1d-b7c4-cf70eedae5c4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c68661f0-c51d-4b13-b95f-7702521a641c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_29cce62a-3c90-430c-8241-61d4164e7dde_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ae10d58c-c6e7-41f8-b098-da91e590f04a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_35cc05d6-cf80-49a7-8a88-4ea0bca81205_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_96cd945a-bfc7-425b-ad2e-cac85c9332c8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_532fcd57-6c5f-47ac-8733-8ea603dbee5b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0ce2496a-ca1a-4f10-9df3-fa8589428c0f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_223d7ce7-3e04-4ee8-bc03-ba2d9624a355_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_efa28cfe-20e0-4292-b0cd-4c86240a908e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_75d93097-8958-4917-ade8-75acd217cce8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ff96adee-5d52-42fc-bd80-7597c846b822_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5df8e8d7-5c06-488a-a425-de499781ce80_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e3838a15-ecb7-4408-994c-f2c66471bc94_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>kprx-20240628_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3c62026a-7aae-40c2-97f2-d20405ae5303,g:4f7b8042-8109-49f0-8333-76a8b38680dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20240628.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_64dbf1be-ba6c-484f-9dea-a6c856303811" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_DocumentType_64dbf1be-ba6c-484f-9dea-a6c856303811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b7f1237a-960f-4fd9-b1d9-8892d9425d0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_DocumentPeriodEndDate_b7f1237a-960f-4fd9-b1d9-8892d9425d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0796c3cd-80eb-4ac7-80e5-dfe2162d3478" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityRegistrantName_0796c3cd-80eb-4ac7-80e5-dfe2162d3478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a027acf7-58c8-466a-bba3-5544df9c713a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a027acf7-58c8-466a-bba3-5544df9c713a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2d8ded84-e9ae-4cd1-9401-2644540fd415" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityTaxIdentificationNumber_2d8ded84-e9ae-4cd1-9401-2644540fd415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b53c4a31-0a09-47ba-ab67-14ddacd83957" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityFileNumber_b53c4a31-0a09-47ba-ab67-14ddacd83957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_17438569-00f4-4809-b4bb-00a5d675dac0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityAddressAddressLine1_17438569-00f4-4809-b4bb-00a5d675dac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_74c8f167-bd41-4b74-aef7-be8864c9f221" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityAddressAddressLine2_74c8f167-bd41-4b74-aef7-be8864c9f221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d0f8373c-1dde-4f35-b100-22a716bae7c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityAddressCityOrTown_d0f8373c-1dde-4f35-b100-22a716bae7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8089d47a-b2e9-432c-ba6c-89d43541aa64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityAddressStateOrProvince_8089d47a-b2e9-432c-ba6c-89d43541aa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_378cea7c-bb2c-4dcc-a91d-9d1d84205e84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityAddressPostalZipCode_378cea7c-bb2c-4dcc-a91d-9d1d84205e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ed555a7-a749-4de0-bb44-5a3fc16c8c5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_CityAreaCode_8ed555a7-a749-4de0-bb44-5a3fc16c8c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_36309d2d-08ec-41fd-95ae-8bd0488e7f9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_LocalPhoneNumber_36309d2d-08ec-41fd-95ae-8bd0488e7f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_90047ec4-8447-471b-95ca-f19cee79be8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_WrittenCommunications_90047ec4-8447-471b-95ca-f19cee79be8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3514e38f-7dd8-472b-b424-867740f37bd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_SolicitingMaterial_3514e38f-7dd8-472b-b424-867740f37bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_435eb28e-e68b-47a1-97f5-119959b4c793" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_PreCommencementTenderOffer_435eb28e-e68b-47a1-97f5-119959b4c793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_761f5bab-ef38-4a8c-b106-d79a17d3d0d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_761f5bab-ef38-4a8c-b106-d79a17d3d0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_49ed3f78-f69d-4517-8d7d-19116f29c00c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_Security12bTitle_49ed3f78-f69d-4517-8d7d-19116f29c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b76c5f5f-3d11-4fa9-bb29-69f643ad590e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_TradingSymbol_b76c5f5f-3d11-4fa9-bb29-69f643ad590e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f7bea239-0621-4c41-92c4-c4bf3c0cb1d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_SecurityExchangeName_f7bea239-0621-4c41-92c4-c4bf3c0cb1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_40b511f9-50a5-40e4-aaea-65068b14b8a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityEmergingGrowthCompany_40b511f9-50a5-40e4-aaea-65068b14b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_290cdf38-d59d-4c8f-9ebf-0021ba942841" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_EntityCentralIndexKey_290cdf38-d59d-4c8f-9ebf-0021ba942841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_298907af-f5c7-459c-8e6d-4c04d61d8587" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb35d432-2f4d-4d61-be95-6e9609d3ac3b" xlink:to="loc_dei_AmendmentFlag_298907af-f5c7-459c-8e6d-4c04d61d8587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140029932649456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 28,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M#SCA6';?\V=7!   &A$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF&MSZC80AO^*QNUTVIDDV.(2D@(S#B$]-#<*G)Y.._T@; &:V)(KRQ#^?5>&
MV+3'K&F_8,OVOCS6KEY)[FV5?DO7G!OR'D<R[3MK8Y+;1B,-UCQFZ95*N(0[
M2Z5C9J"I5XTTT9R%>5 <-:CK=AHQ$](9]/)K$SWHJ<Q$0O*))FD6QTSO[GBD
MMGW'<SXN3,5J;>R%QJ"7L!6?<?,YF6AH-0J54,1<ID))HOFR[_C>[1UMVX#\
MB5\%WZ9'Y\2^RD*I-]L8AWW'M40\XH&Q$@P.&S[D4625@..O@ZA3_*<-/#[_
M4'_(7QY>9L%2/E31%Q&:==_I.B3D2Y9%9JJVG_CAA7+ 0$5I_DNV^V=;+8<$
M66I4? @&@EC(_9&]'SKB**#IG@B@AP":<^__**>\9X8->EIMB;9/@YH]R5\U
MCP8X(6U69D;#70%Q9C!4&ZY[#0-2]D(C.(3=[</HB;"?,WE%:/>"4)>V_AG>
M (("@Q88--=K8ACD#W^1&@V)^K.*:*_0JE:PU7N;)BS@?0?*,^5ZPYW!=]]X
M'?='A*]9\#4Q]<&]"C*H14/FNX17P>'AW<M'!*)50+3.@YAP+51(1C(DD/1*
M'ERI2%]=_MH%6AL5'$DCS(Y,^4K8# +C"XLKP7"=Q_'KU">33_[TV1^./L_'
M0_]I=D'&+\,KA+)34';.H1S+0.E$:69]X8+,#/0A49H,52:-WL$QK$3'Q>]'
M".%U07A]#N&<O9-Q"*D62Q'DF.0EBQ?5(Q57O.E>NJU6DW:Q-'<+O.XY> \B
MX@@0KN&ZWF6ST[FF",]-P7-S#H\?AC#DTXN/$_($SY%769E%7+'9I#"N B&%
M82FYBS8A5GB>6]JL^_])YUM5:<&XY"P34+>>BW6D=S0/>/\)<&A;,"CF:BLK
MX>KD#GV(P96S@X>:^U=PQ9"=:+41,JA,=(WFT,?0RHG!PZW]WV@3E1H6D=]%
M<M)':A1O:CS9*^<+#[?Y/(<^+-9.H^ "W787 REG!P^W]2<50)],UDIBOE$C
M0FGK\J;CNAA1.1-XN%M_T<(8+J%CXCB3!Y--*ZEPH26+4HXAE=;OX4X]4Y$(
MA!%R19ZAO+5@424/KE++4WJ]AQOU1//+ +J'P_C:KWVX#&&5]KI<GL@?KE=+
M5KJ^AYOT5V3C-,V K!80EZT#I*7;4]R:Y\+ #*F6Q*/?+WX@,QYD4&^[RE4M
MKF3K$V;_F5'!VP7YUKUR/9(P338LRE#6TO@I[M1SS4);<[-=O%"5%5<C\#B9
M_H:1'.T!<$?^Z"8R>@_63*[XR45DC="+/[OW?\&82GNG9]G[*.9Z97OI)U P
M:VL;"9/5"<4%:XNL='>*F_,!;0@#0(.[CJ'VW\DCKX;"I5Q8E#6O:=M#]W*E
MW5/<J7T8E&$^,!\BMJKDP05.=E+C:*=KOQH\,YN6E$1\"4+NU37HZOU&?-\P
M*LDWOPME8"N=GZXY Y>P#\#]I5+FHV'WT\7GD,'?4$L#!!0    (  \XX5B?
MH!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1
M&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMW
MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<
M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20
MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!
M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B
M+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM
M(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS
M8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS
MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5
M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S
MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41
MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS
M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U
M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,
M/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#
M!!0    (  \XX5B7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ #SCA6*K$(A8S 0  (@(   \   !X;"]W;W)K8F]O
M:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:
MTE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P
M9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<'
M)O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-
MY&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_
M4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3
M#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#
M!!0    (  \XX5@D'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z
M=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2
MO6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV
M-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^
M 5!+ P04    "  /..%899!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S
M72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2
M%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;
M$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!
MZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKB
MRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'
MG2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"
M[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (  \XX5@'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M#SCA6-JQQ:SM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ #SCA6)E<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  /..%8=M_S
M9U<$   :$0  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ #SCA6)^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20240628.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="kprx-20240628.htm">kprx-20240628.htm</File>
    <File>kprx-20240628.xsd</File>
    <File>kprx-20240628_lab.xml</File>
    <File>kprx-20240628_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kprx-20240628.htm": {
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20240628",
   "dts": {
    "inline": {
     "local": [
      "kprx-20240628.htm"
     ]
    },
    "schema": {
     "local": [
      "kprx-20240628.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20240628_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20240628_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eyegatepharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20240628.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20240628.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001372514-24-000068-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-24-000068-xbrl.zip
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MFT KI7$,@09*XMA"I%")PM3&JL"RW4E,0Q9MD:NMZ7>.2JPK>JA>IZJ)+#2
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MR,29$O'CCUZAA;^%O;X\PK$2&.1J+%%:VD-9HDIV.Q_XVNXS<9G?A4CH&(J
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M9VJ6#1 :[?Y9^W\?3J-Y'J9AS[/12!9L,&,61>UA>E]   I*XEL(J3N2P;S
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M0-E4OU\V?870B=V89:&V%T=[<;071WMQ=(\X,FOWBJ.Y -)1;TKZL^+]Q[V
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MZG("  !_!P  $0   &MP<G@M,C R-# V,C@N>'-DS55;;YLP%'[/K_!XGL%
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MR^J,"STSV3?1JH<;_>YDD<UO9GK]W'6IT^ZPL[)L1:VS9'66**ZS_&N?V&1
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M# '5/(:A$EI'PI:$5N0CH_"H%=1B]BRTW>^'P=N3&PV6=IQPZ$S=BX=VI-&
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M<)]S)%E?&8[VJG>2P'9^:PA9EEE%K)((=0"*$4A),BNB9[G7/AO6Q_C:6C\
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MM!_M7R:.W_P/4$L! A0#%     @ #SCA6)Y/MTU0#0  RB\   X
M     ( !     &5X:&EB:70Y.3$N:'1M4$L! A0#%     @ #SCA6 )6+RNO
M'0  9M   !$              ( !? T  &MP<G@M,C R-# V,C@N:'1M4$L!
M A0#%     @ #SCA6#HY0^IR @  ?P<  !$              ( !6BL  &MP
M<G@M,C R-# V,C@N>'-D4$L! A0#%     @ #SCA6+<^9'I$"@  %%@  !4
M             ( !^RT  &MP<G@M,C R-# V,CA?;&%B+GAM;%!+ 0(4 Q0
M   (  \XX5AD&]=NV08   (S   5              "  7(X  !K<')X+3(P
D,C0P-C(X7W!R92YX;6Q02P4&      4 !0!  0  ?C\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>kprx-20240628_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20240628.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-06-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
